Breast cancer (BC) is the most common cancer among women, making it essential to have an accurate and dependable system for diagnosing benign or malignant tumors. It is essential to detect this cancer early in order to inform subsequent treatments. Currently, fine needle aspiration (FNA) cytology and machine learning (ML) models can be used to detect and diagnose this cancer more accurately. Consequently, an effective and dependable approach needs to be developed to enhance the clinical capacity to diagnose this illness. This study aims to detect and divide BC into two categories using the Wisconsin Diagnostic Breast Cancer (WDBC) benchmark feature set and to select the fewest features to attain the highest accuracy. To this end, this study explores automated BC prediction using multi-model features and ensemble machine learning (EML) techniques. To achieve this, we propose an advanced ensemble technique, which incorporates voting, bagging, stacking, and boosting as combination techniques for the classifier in the proposed EML methods to distinguish benign breast tumors from malignant cancers. In the feature extraction process, we suggest a recursive feature elimination technique to find the most important features of the WDBC that are pertinent to BC detection and classification. Furthermore, we conducted cross-validation experiments, and the comparative results demonstrated that our method can effectively enhance classification performance and attain the highest value in six evaluation metrics, including precision, sensitivity, area under the curve (AUC), specificity, accuracy, and F1-score. Overall, the stacking model achieved the best average accuracy, at 99.89%, and its sensitivity, specificity, F1-score, precision, and AUC/ROC were 1.00%, 0.999%, 1.00%, 1.00%, and 1.00%, respectively, thus generating excellent results. The findings of this study can be used to establish a reliable clinical detection system, enabling experts to make more precise and operative decisions in the future. Additionally, the proposed technology might be used to detect a variety of cancers.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608611 | PMC |
http://dx.doi.org/10.3390/life13102093 | DOI Listing |
Medeni Med J
December 2024
Dokuz Eylül University Faculty of Medicine, Departmet of Medical Pathology, İzmir, Türkiye.
Objective: Angiotropism/perivascular invasion (PVI) is an emerging topic in various types of cancer, with studies primarily focusing on melanoma. However, limited data are available on the significance of PVI in breast cancer. This study aimed to assess the prognostic significance of PVI in breast cancer and its correlation with traditional clinicopathological prognostic parameters.
View Article and Find Full Text PDFGut Microbes
December 2025
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Establishment of the gut microbiota during infancy is critical for host health with long-lasting implications. In this orchestrated process, microbial assembly is influenced by an increasing number of genetic and environmental factors, among which breastfeeding is considered as one of the most significant drivers for infant gut microbiota development. As the optimal diet for the infants, maternal milk provides numerous nutritional, microbial, and bioactive components to ensure the most adequate microbial growth and development of a 'healthy' gut microbiota during early life.
View Article and Find Full Text PDFCancer Res Treat
December 2024
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Purpose: Multigene assays guide treatment decisions in early-stage hormone receptor-positive breast cancer. OncoFREE, a next-generation sequencing assay using 179 genes, was developed for this purpose. This study aimed to evaluate the concordance between the Oncotype DX (ODX) Recurrence Score (RS) and the OncoFREE Decision Index (DI) and to compare their performance.
View Article and Find Full Text PDFFront Cardiovasc Med
December 2024
Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: Cardiovascular biomarkers are crucial for monitoring cancer therapy-related cardiac toxicity, but the effects on early stage are still inadequate. To screen biomarkers in patients with breast cancer who receive anthracycline-containing chemotherapy, we studied the behavior of six biomarkers during chemotherapy and their association with chemotherapy-related cardiac toxicity.
Methods: In a prospective cohort of 73 patients treated with anthracycline-containing chemotherapy, soluble suppression of tumorigenicity 2 (sST2), high-sensitivity cardiac troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), myoglobin, creatine kinase isoenzyme MB, and heart-fatty acid binding protein were measured at baseline, during chemotherapy cycle (C1-C6).
In Silico Pharmacol
December 2024
Department of Bioinformatics, Alagappa University, Karaikudi, 630003 Tamil Nadu India.
Unlabelled: Drug repurposing is necessary to accelerate drug discovery and meet the drug needs. This study investigated the possibility of using fluvoxamine to inhibit the cellular metabolizing enzyme NUDT5 in breast cancer. Computational and experimental techniques were used to evaluate the structural flexibility, binding stability, and chemical reactivity of the drugs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!